Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 29 ... researchers from University of Wisconsin and three other institutions have identified a protein that is central to processes that cause oxidative damage to cells and lead to ... loss.The findings help point the way toward a new target for antioxidant therapies and will be published online this week in the Proceedings of the National Academy of ...
2009 NOV 25 ... nanoparticles were efficiently delivered to K562 cells and downregulated the bcl-2 protein expression by 34 +/- 6% and 57 +/- 3% respectively." Wu and colleagues ... State:OH, Country:United States, Life Sciences, Molecular Pharmacology, Molecular Therapies, Therapy, Treatment, Pharmaceuticals, Molecular Pharmaceutics, Ohio State University. ...
2009 NOV 23 ... and adipocytes. Furthermore, the in vitro differentiation was confirmed at both the protein and gene expression levels. Transplantation of hDPCs-expanded ex vivo in the presence of ... serum are rich in mesenchymal stem cells or progenitor cells and useful for cell-based therapies to treat dental diseases." Morito and colleagues published their study in ...
2009 NOV 23 ... using fluorescence in situ hybridization with combined promyelocytic leukemia (PML) protein immunofluorescence. The ALT phenotype was identified in 3 of 21 HER-2-positive cases, ... concluded: "As cancers using the ALT pathway are predicted to be resistant to therapies based on telomerase inhibition, these results may have therapeutic consequences." ...
2009 NOV 23 ... According to recent research from the United States, "IGF-binding protein 3 (IGFBP-3) promotes apoptosis by both IGF-dependent and -independent mechanisms. We ... intrinsic regulation of IGFBP-3 action may enhance the development of potential cancer therapies. (Molecular Endocrinology 23: 1624-1633, 2009)." Cobb and colleagues ...
2009 NOV 23 ... resistance showed a dramatic increase in the amount of the cleaved form of the MUC1 protein, called MUC1*. We recently reported that MUC1* functions as a growth factor receptor on ... resistance to trastuzumab within the first year of treatment. Follow-on ''salvage'' therapies have prolonged life for this group but have not been curative. Thus, it is critically ...
2009 NOV 27 ... been shown to also act as an inhibitor of hair cell development. Finally, the motor protein myosin II regulates extension of the organ of Corti and the alignment of hair cells and ... "In addition, targeted modulation of these same factors could be developed as therapies for hair cell regeneration. Recent findings Results from experiments using transgenic ...
2009 NOV 23 ... being investigated." "Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that raises HDL-C and reduces LDL-C when administered alone or with a ... high despite statin therapy to lower low-density lipoprotein cholesterol (LDL-C). New therapies to raise high-density lipoprotein cholesterol (HDL-C) are currently being ...
2009 NOV 27 ... Scientists have devised an innovative way to disarm a key protein considered to be "undruggable," meaning that all previous efforts to develop a drug ... target transcription factors, both for use as scientific tools in the laboratory and as therapies in the clinic," said senior author James Bradner, a Harvard chemical biologist and ...
2009 NOV 23 ... neurites in both the hippocampi of transgenic mice overexpressing amyloid precursor protein (APP) and in the human brain affected with AD," investigators in the United States ... therapeutic approaches to AD based on this restoration that could work independently of therapies aimed at lowering A beta levels in the brain." Smith and colleagues ...
2009 NOV 23 ... fibroblasts. ET-1-induced activation of PI3K/AKT is dependent on p38 mitogen-activated protein kinase (MAPK), but not extracellular signal-regulated kinase (ERK) 1/2, INK, or ... Medical Department. The researchers concluded: "The potential for novel therapies targeting the convergence of prosurvival signaling pathways activated by these two ...
2009 NOV 23 ... enzyme cleaves off the signal peptide from secreted proteins, making it essential for protein secretion, and hence for bacterial cell viability. S. epidermidis encodes three putative ... source of nosocomial biofilm-associated infections. In the search for new antibacterial therapies, the type I signal peptidase (SPase I) serves as a potential target for development of ...
2009 NOV 23 ... laboratory to develop vaccines, diagnostics, and therapies. Proteomics is the study of protein structure and function, helping scientists better understand the causes of disease, ...
2009 NOV 23 ... mouse embryonic stem (mES) cells as model cell lines, plasmid encoding green fluorescent protein (pGFP) and secreted alkaline phosphatase (pSEAP) as the reporter gene, and commercially ... Biotechnology, DNA, Gene Therapy, Genetics, Genomics, Molecular Pharmacology, Molecular Therapies, Pharmaceuticals, Therapy, Treatment, Ohio State University. This article ...
2009 NOV 23 ... the anticancer efficacy of SQgem has been investigated by flow cytometry analysis and protein expression profiling of L1210wt cells treated in vitro with the squalenoyl gemcitabine ... Trials, Enzymes, Gemcitabine, Immunosuppressant, Molecular Pharmacology, Molecular Therapies, Nucleoside Analog, Oncology, Pharmaceuticals, Pre-Trials Research, ...
2009 NOV 23 ... by the heart, lungs, kidney, and bone." "Monocyte chemoattractant protein-1 (MCP-1), a chemotactic cytokine, is involved in the progression of glomerular and ... 0.0001). The lack of availability of urine biomarkers has hampered development of new therapies for lupus nephritis. Urine MCP-1 and OPG were both associated with measures of lupus ...
2009 NOV 23 ... in the U.S. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials - CONSERV™-1 and CONSERV™-2 - for the reduction ... employees are committed to building the world's leading company focused on providing therapies for acutely ill patients. To ensure that mission's success, we depend on retaining and ...
